CLINICAL TRIAL: GENTAMICIN IN DUCHENNE MD

$101,462M01FY2009RRNIH

University Of Kansas Medical Center, Kansas City KS

Investigators

Linked publications & trials

Paper 37965761 Paper 37717845 Paper 35005320 Paper 34554658 Paper 34401721 Paper 33305291 Paper 32807060 Paper 32634120 Paper 31874800 Paper 31171572 Paper 31088850 Paper 30922668 Paper 30591038 Paper 29854969 Paper 29564978 Paper 29306517 Paper 29290310 Paper 29203126 Paper 29118087 Paper 28532709 Paper 28460625 Paper 28187125 Paper 28027795 Paper 27993381 Paper 27779124 Paper 27484667 Paper 27043532 Paper 26823553 Paper 26797708 Paper 26504889 Paper 26239997 Paper 26231556 Paper 25908323 Paper 25690663 Paper 25399733 Paper 25399731 Paper 24904092 Paper 24780290 Paper 24735819 Paper 24724042 Paper 24576800 Paper 24574235 Paper 24485488 Paper 24183837 Paper 24107679 Paper 24062599 Paper 23992649 Paper 23520042 Paper 23388170 Paper 23254633 Paper 23124935 Paper 23089511 Paper 22903151 Paper 22842866 Paper 22717465 Paper 22344503 Paper 22205355 Paper 22133248 Paper 22020383 Paper 21903983 Paper 21745566 Paper 21674518 Paper 21574893 Paper 21531480 Paper 21475079 Paper 21357834 Paper 21320368 Paper 21098656 Paper 20947841 Paper 20672296 Paper 20615058 Paper 20542855 Paper 20530663 Paper 20517938 Paper 20442494 Paper 20385908 Paper 20222151 Paper 20164583 Paper 20128333 Paper 20125103 Paper 20110598 Paper 20089507 Paper 20065246 Paper 20009161 Paper 20007751 Paper 19917643 Paper 19815976 Paper 19812458 Paper 19743457 Paper 19661621 Paper 19584447 Paper 19571736 Paper 19520990 Paper 19447923 Paper 19420195 Paper 19015492 Paper 18949779 Paper 18843002 Paper 18772275 Paper 18625967

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary purpose of this study is to see if gentamicin given twice a week for a total of 6 months can be given safely. One of the secondary goals of the study is to determine if gentamicin can help correct the gene defect and allow the body to make enough dystrophin (a protein which is absent in DMD) to let the muscles function. The other secondary goal is to evaluate the effects of gentamicin on muscle strength.

View original record on NIH RePORTER →